Cargando…

JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment

Recent advances in cancer immunotherapy have attracted great interest due to the natural capacity of the immune system to fight cancer. This field has been revolutionized by the advent of chimeric antigen receptor (CAR) T cell therapy that is utilizing an antigen recognition domain to redirect patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khanali, Javad, Azangou-Khyavy, Mohammadreza, Boroomand-Saboor, Melika, Ghasemi, Mobina, Niknejad, Hassan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220211/ https://www.ncbi.nlm.nih.gov/pubmed/34177890 http://dx.doi.org/10.3389/fimmu.2021.638639

Ejemplares similares

CRISPR/Cas: From Tumor Gene Editing to T Cell-Based Immunotherapy of Cancer
por: Azangou-Khyavy, Mohammadreza, et al.
Publicado: (2020)

Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs
por: Khanali, Javad, et al.
Publicado: (2021)

Engineering chimeric autoantibody receptor T cells for targeted B cell depletion in multiple sclerosis model: An in-vitro study
por: Sahlolbei, Maryam, et al.
Publicado: (2023)

MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreak
por: Jamalkhah, Monire, et al.
Publicado: (2021)

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
por: Rodriguez-Garcia, Alba, et al.
Publicado: (2020)

Global, regional, and national quality of care of gallbladder and biliary tract cancer: a systematic analysis for the global burden of disease study 1990–2017
por: Khanali, Javad, et al.
Publicado: (2021)

AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3
por: Ye, Hua, et al.
Publicado: (2023)

Prevalence of plasma lipid abnormalities and associated risk factors among Iranian adults based on the findings from STEPs survey 2021
por: Khanali, Javad, et al.
Publicado: (2023)

The burden of metabolic risk factors in North Africa and the Middle East, 1990–2019: findings from the Global Burden of Disease Study
por: Malekpour, Mohammad-Reza, et al.
Publicado: (2023)

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
por: Xia, An-Liang, et al.
Publicado: (2017)

Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
por: Yan, Lingli, et al.
Publicado: (2018)

Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2020)

Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapies for the Treatment of Primary Brain Tumors
por: Mount, Christopher W., et al.
Publicado: (2022)

Emerging advances in nanobiomaterials-assisted chimeric antigen receptor (CAR)-macrophages for tumor immunotherapy
por: Zhang, Yanan, et al.
Publicado: (2023)

Wastewater treatment plants, an “escape gate” for ESCAPE pathogens
por: Marutescu, Luminita Gabriela, et al.
Publicado: (2023)

Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating
por: Hamieh, Mohamad, et al.
Publicado: (2023)

Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing
por: Liao, Qibin, et al.
Publicado: (2020)

Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)‐T therapy has potential to reduce escape from single‐target CAR‐T with no more hematotoxicity
por: Wang, Zhenzhen, et al.
Publicado: (2023)

Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
por: Li, Jian, et al.
Publicado: (2018)

A Systematic Review of the Role of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in the Treatment of Solid Tumors
por: Siddiqui, Raheel S, et al.
Publicado: (2021)

The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors
por: Hadiloo, Kaveh, et al.
Publicado: (2023)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
por: Abbasi, Samane, et al.
Publicado: (2022)

Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
por: Galli, Eugenio, et al.
Publicado: (2021)

Humanized Chimeric Antigen Receptor (CAR) T cells
por: Kozani, Pouya Safarzadeh, et al.
Publicado: (2021)

Minimizing leukemia escape: implementing a dual anti-CD20- and CD19-scFv-based chimeric antigen receptor (CAR)
por: Schneider, Dina, et al.
Publicado: (2015)

Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors
por: Spear, Paul, et al.
Publicado: (2013)

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
por: Hege, Kristen M., et al.
Publicado: (2017)

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
por: Keshavarz, Ali, et al.
Publicado: (2022)

How tumors escape oblivion
por: LeBrasseur, Nicole
Publicado: (2002)

The ART of tumor immune escape
por: Wennerberg, Erik, et al.
Publicado: (2022)

The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis
por: Wu, Yingcheng, et al.
Publicado: (2017)

Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy
por: Katiyar, Vatsala, et al.
Publicado: (2023)

Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
por: Masoumi, Javad, et al.
Publicado: (2021)

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
por: Benmebarek, Mohamed-Reda, et al.
Publicado: (2019)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells
por: Tokatlian, Talar, et al.
Publicado: (2022)

In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors
por: Sun, Zhichen, et al.
Publicado: (2022)

Dual-inhibitory domain iCARs improve the efficiency of the AND-NOT gate CAR T strategy
por: Bangayan, Nathanael J., et al.
Publicado: (2023)

Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells
por: Rad S. M., Ali Hosseini, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_083vj61n065rhnmcmja53dr8jb